Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Blanchet

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Clinical Pharmacokinetics|September 12, 2008
Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patientsBenoit Blanchet, Vincent Jullien, Christophe Vinsonneau, et al.
Clinical Toxicology (Philadelphia, Pa.)|September 13, 2007
A case of mixed intoxication with isopropyl alcohol and propanol-1 after ingestion of a topical antiseptic solutionBenoit Blanchet, Antoine Charachon, Stéphanie Lukat, et al.
Fundamental & Clinical Pharmacology|April 1, 2006
Distribution of calcineurin activity in blood cell fractions and impact of tacrolimus inhibitionBenoit Blanchet, Anne Hulin, Bijan Ghaleh, et al.
Biomedicines|June 2, 2021
Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with ElisaAurélien Millet, Nihel Khoudour, Jérôme Guitton, et al.
Molecules (Basel, Switzerland)|April 3, 2021
Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human PlasmaAurélien Millet, Nihel Khoudour, Dorothée Lebert, et al.
Cancers|January 8, 2023
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal CancerFlorent Puisset, Mourad Mseddi, Loïc Mourey, et al.
Melanoma Research|May 2, 2015
Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanomaLilia Sakji-Dupré, Emilie Le Rhun, Carole Templier, et al.
Anti-Cancer Drugs|February 15, 2012
Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcomaOlivier Mir, Pascaline Boudou-Rouquette, Frédérique Larousserie, et al.
Molecular Pharmacology|May 15, 2021
Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma CellsRania Harati, Marc Vandamme, Benoit Blanchet, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 23, 2010
In vitro influence of fatty acids and bilirubin on binding of mycophenolic acid to human serum albuminYoann Vial, Michel Tod, Marilyne Hornecker, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Clinical Pharmacokinetics|September 12, 2008
Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patientsBenoit Blanchet, Vincent Jullien, Christophe Vinsonneau, et al.
Clinical Toxicology (Philadelphia, Pa.)|September 13, 2007
A case of mixed intoxication with isopropyl alcohol and propanol-1 after ingestion of a topical antiseptic solutionBenoit Blanchet, Antoine Charachon, Stéphanie Lukat, et al.
Fundamental & Clinical Pharmacology|April 1, 2006
Distribution of calcineurin activity in blood cell fractions and impact of tacrolimus inhibitionBenoit Blanchet, Anne Hulin, Bijan Ghaleh, et al.
Biomedicines|June 2, 2021
Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with ElisaAurélien Millet, Nihel Khoudour, Jérôme Guitton, et al.
Molecules (Basel, Switzerland)|April 3, 2021
Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human PlasmaAurélien Millet, Nihel Khoudour, Dorothée Lebert, et al.
Cancers|January 8, 2023
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal CancerFlorent Puisset, Mourad Mseddi, Loïc Mourey, et al.
Melanoma Research|May 2, 2015
Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanomaLilia Sakji-Dupré, Emilie Le Rhun, Carole Templier, et al.
Anti-Cancer Drugs|February 15, 2012
Durable clinical activity of single-agent bevacizumab in a nonagenarian patient with metastatic alveolar soft part sarcomaOlivier Mir, Pascaline Boudou-Rouquette, Frédérique Larousserie, et al.
Molecular Pharmacology|May 15, 2021
Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma CellsRania Harati, Marc Vandamme, Benoit Blanchet, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 23, 2010
In vitro influence of fatty acids and bilirubin on binding of mycophenolic acid to human serum albuminYoann Vial, Michel Tod, Marilyne Hornecker, et al.
Pageof 11